for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mabion SA

MABP.WA

Latest Trade

73.60PLN

Change

-1.70(-2.26%)

Volume

2,826

Today's Range

73.40

 - 

75.50

52 Week Range

66.00

 - 

102.80

As of on the Warsaw Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Mabion Q2 Net Loss Shrinks To 16.7 Mln Zlotys

Sept 13 (Reuters) - Mabion SA <MABP.WA>: :REPORTED ON THURSDAY Q2 NET LOSS OF 16.7 MILLION ZLOTYS VERSUS LOSS OF 26.8 MILLION ZLOTYS YEAR AGO .Q2 OPERATING LOSS 17.7 MILLION ZLOTYS VERSUS LOSS OF 22.8 MILLION ZLOTYS YEAR AGO.

Mabion Plant In Konstantynow Lodzki Gets Second GMP Certificate

Aug 19 (Reuters) - Mabion SA <MABP.WA>::ITS SCIENTIFIC AND INDUSTRIAL MEDICAL BIOTECHNOLOGY PLANT IN KONSTANTYNOW LODZKI GETS GMP CERTIFICATE.SAYS ITS IS SECOND CERTIFICATE RECEIVED AS A RESULT OF INSPECTION COMMISSIONED BY EMA IN PROCESS OF LAUNCHING MABIONCD20 DRUG.

Mabion Says EMA May Recommend Co's Facility For Production of MabionCD20 Drug

July 25 (Reuters) - Mabion SA <MABP.WA>::SAYS EMA SAYS FOLLOWING INSPECTION OF MABIONCD20 DRUG, CO' PRODUCTION PROCESSES ARE IN LINE WITH GOOD MANUFACTURING PRACTICE.SAYS INSPECTION FINDINGS ALLOW EMA TO RECOMMEND KOMPLEKS NAUKOWO PRZEMYSŁOWY BIOTECHNOLOGII MEDYCZNEJ MABION AS PRODUCTION FACILITY OF SAID DRUG.

Mabion Production Complex In Konstantynow Lodzki Gets GMP Certificate

July 23 (Reuters) - Mabion SA <MABP.WA>::SAYS GETS GMP (GOOD MANUFACTURING PRACTICE) CERTIFICATE FROM GIF FOR CO'S PRODUCTION COMPLEX IN KONSTANTYNOW LODZKI REGARDING PRODUCTION OF RYTUKSYMAB ACTIVE SUBSTANCE.SAYS OBTAINING GMP CERTIFICATE IS RELATED TO ALLOWING MABIONCD20 MEDICINE ON THE MARKET.

Mabion Q1 Net Loss Widens To 15.0 Mln Zlotys

May 17 (Reuters) - MABION SA <MABP.WA>::REPORTED ON THURSDAY Q1 NET LOSS OF 15.0 MILLION ZLOTYS VERSUS LOSS OF 14.3 MILLION ZLOTYS YEAR AGO.Q1 OPERATING LOSS OF 14.5 MILLION ZLOTYS VERSUS LOSS OF 14.1 MILLION ZLOTYS YEAR AGO.

Artur Chabowski Steps Down As CEO of Mabion

April 25 (Reuters) - Mabion SA <MABP.WA>::CEO ARTUR CHABOWSKI STEPS DOWN AS OF JUNE 30.

Mabion FY Net Loss Widens To 68.9 Mln Zlotys

April 10 (Reuters) - Mabion SA <MABP.WA>::FY NET LOSS 68.9 MILLION ZLOTYS VERSUS LOSS OF 57.9 MILLION ZLOTYS YEAR AGO.FY OPERATING LOSS 64.6 MILLION ZLOTYS VERSUS LOSS OF 62.4 MILLION ZLOTYS YEAR AGO.

Mabion Updates Strategy Of Medicinal Product Development

April 3 (Reuters) - Mabion SA <MABP.WA>::UPDATES ITS STRATEGY OF MEDICINAL PRODUCT DEVELOPMENT.PLANS TO LAUNCH RESEARCH AND DEVELOPMENT WORKS ON BIOSIMILAR DRUGS IN FIELD OF AUTOIMMUNITY, METABOLIC DISEASES AND ONCOLOGY.

Mabion Q3 Net Loss Narrows To 11.1 Mln Zlotys

Nov 16 (Reuters) - MABION SA <MABP.WA>::SAID ON THURSDAY Q3 NET LOSS WAS AT 11.1 MLN ZLOTYS VS LOSS OF 13.2 MLN ZLOTYS YR AGO.Q3 OPERATING LOSS 11.8 MLN ZLOTYS VS LOSS OF 13.2 MLN ZLOTYS YR AGO.

Mabion Files Second Patent Application

Oct 29 (Reuters) - MABION SA <MABP.WA>::SAID ON FRIDAY IT FILED A SECOND PATENT APPLICATION FOR ITS INVENTION FROM AREA OF ​​APPLICATION OF MABIONCD20 IN TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS 'LOW AGGREGATE ANTI CD20 LIGAND FORMULATION'.IN DEC. 2017 CO FILED FOR PATENT FOR ITS INVENTION 'COMBINATION THERAPY OF MULTIPLE SCLEROSIS COMPRISING A CD20 LIGAND' nFWN1O50T6.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up